You coined the Wellness Gap as a quantifiable delta. The portcos narrow it. The pattern-detection question you raised in October — substance over hype, grounded in science — is what makes the delta defensible across 50+ portcos, or doesn't.
50+ portcos · 7 evidence regimes · one delta · one substrate
The framework you publish is what your portcos sell. The pattern-detection question you raised is what makes the recursion hold — or break.
"The Wellness Gap: the quantifiable delta that has grown dramatically over the past two decades as economic indicators such as GDP per capita have increased while measures of overall wellbeing, including physical and mental health, have stagnated or decreased."
- GDP_per_capita (t) · ↑ rising · two decades
- Wellbeing (t) · ↓ stagnant / declining
- Δ Wellness Gap · = GDP − Wellbeing · widening
"It starts with substance over hype. The most promising companies are grounded in science and validated data. We love 'informed' enthusiasm, but passion without a data-driven plan can be a red flag."
FIG. ── WELLNESS GAP (t) = GDP_per_capita (t) − Wellbeing (t)
Evergreen fund · 50+ portcos · 9 years deploying. Biometrics (Oura), clinical biomarkers (Function), psychedelic trials (Compass · ATAI), women's-health (Maven), workplace mental health (Spring), supplements (SuppCo), connection (Bumble).
No two portcos share an evidence regime. Oura's HRV does not compose with Compass's RCT. Function's lab panel does not compose with SuppCo's product test. The delta stays clean. The cross-portfolio pattern drifts unmeasured.
Cross-portfolio pattern detection now operational, not aspirational.
- Oura Series F · "show recovery against fund cohorts." → cross-portfolio answer must compose, not just be cited.
- Function Health post-Ezra · "show lab cohort vs wearable cohort." → without substrate, cross-portfolio answers live in IC memos and partner judgment.
The delta is the public layer. The portco evidence regimes are the recursive layer. The substrate is the same primitive at both.
You back Oura for biometric signal, Function Health for clinical biomarker, Compass for RCT outcomes, Spring for workplace mental health. Each ships rigor — substance, science, data — to its own customers. The discipline they ship is the discipline your fund needs at 50-portco scale. One delta. Two layers.
- AUDIT CHAIN
- every reading per portco hash-chained, append-only, never-deletable, evidence mode tagged at emission [verified] [model-derived] [self-reported] [partner-supplied] [stale]. Cross-portfolio composition at the chain — biometric, clinical, RCT, telemetry held side-by-side.
- METHODOLOGY OVERLAY · L2 YAML
- each portco's Rₓ encoded as inspectable YAML. The Wellness Gap delta you publish externally becomes the same artifact the fund operates on internally — versioned, portable, replay-tested.
FIG. ── DELTA LAYER · PORTCO EVIDENCE LAYER · ONE PRIMITIVE
FIG. ── AUDIT CHAIN · CROSS-PORTFOLIO COMPOSITION · HASH-LINKED · APPEND-ONLY · NEVER-DELETABLE
built for cross-portfolio pattern detection · at 50-portco scale
Pick one portco. We rebuild its evidence chain in synthetic. You see whether it composes with another portco's regime in the substrate, or doesn't.
Phase 0 is not a pilot. Two-week structural diagnostic against one portco — synthetic data only, no production access. The question it answers is narrow and load-bearing: under cross-portfolio pattern detection across two methodology versions, does this portco's evidence regime compose with a second portco's — and does the Wellness Gap delta hold beneath them both? Three artifacts. You keep all three whether you continue or not.
ONE PORTCO · TWO METHODOLOGY VERSIONS · SYNTHETIC EVIDENCE · CROSS-PORTFOLIO COMPOSITION REPLAY
THE DIAGNOSTIC · WHAT TWO WEEKS PRODUCES
- 01Methodology overlay v0.1
The portco's Rₓ encoded as L2 YAML — evidence regime made inspectable. Composition slot open for a second portco. Versioned. Portable. Runs in your environment without us.
- 02Audit chain replay
Chain populated against synthetic readings across two methodology versions — cross-portfolio composition simulated before the next deployment cycle cites it. Drift visible or not.
- 03Cost model
Framed against evergreen deployment cadence, cross-portfolio pattern detection at 50+ portcos, and the data-driven plan you publicly require of founders. Risks named. Where this approach breaks.
Pressure-test the substrate. Ask where it breaks.
The substrate answers in its own voice — the same primitive we'd install on one of your portcos. Not a demo. The actual reasoning surface.
STREAMING · κ ≥ 0.85 · ANONYMITY HOLDS · CITATIONS BY DEFAULT
If the pattern reads true, the next step is to test whether one portco is the right Phase 0 target.
If relevant, we can send a short async questionnaire — no call needed — and build a no-charge synthetic-data Phase 0 PoC "Able AI OS". Within two weeks, replay one portco's evidence chain against a second portco's regime — and watch whether the Wellness Gap delta holds beneath them both.
Published impact-carry formula meets non-linear evidence-chain growth — and an SFDR 2.0 replay.
Analytical reconstruction · Article 9 fund under impact-tied carry economics · methodology and audit-chain pattern. No live engagement. Design-partner slot open.
Article 9 consumer impact at £80M · per-portco evidence reconstructability under SFDR 2.0.